NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

NTRK遗传基因融合阳性癌症的开发平台医药品:市场机会的评估,市场趋势,流行病学的研究,开发中产品分析 (2020年下半年)

NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020

出版商 GervanoRA Data Services LLP 商品编码 979839
出版日期 内容资讯 英文 290 Pages
订单完成后即时交付
价格
NTRK遗传基因融合阳性癌症的开发平台医药品:市场机会的评估,市场趋势,流行病学的研究,开发中产品分析 (2020年下半年) NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020
出版日期: 2020年12月30日内容资讯: 英文 290 Pages
简介

本报告提供全球NTRK融合遗传基因阳性固体癌治疗药的开发平台医药品的市场相关分析,疾病概要和疫情趋势预测,未满足需求与市场机会,主要的资本交易的趋势 (M&A,事业合作等),开发中产品的分析与临床实验的进展,现在、未来的竞争环境,主要企业的SWOT分析,新企业的简介与市场机会等资讯汇整,为您概述为以下内容。

目录

第1章 简介

第2章 摘要整理

  • 报告概要
  • TRK抑制剂市场竞争情形:近来的主要趋势
  • 主要的分析结果
    • 促进因素
    • 阻碍因素
    • 市场机会
  • TRK抑制剂市场竞争情形:市场动态
    • 未满足需求与市场需求:新的治疗药的情况
    • 未满足需求与市场需求:各给药途径
    • 未满足需求与市场需求:各地区

第3章 开发平台分析:未来展望

  • 开发平台分析:现状比较
    • 各开发阶段
    • 各地区
    • 各给药途径
    • 各分子类型
    • 各适应症
    • 企业的各类型

第4章 TRK抑制剂疗法:概要与流行病学研究

  • 简介
  • TRK抑制剂疗法:开发阶段的评估
  • TRK抑制剂疗法的范围
  • NTRK融合癌症患者的检测
  • 癌症的NTRK遗传基因融合的发现
  • 已批准TRK抑制剂产品
  • NTRK融合遗传基因的流行病学的研究
    • 全球过去的研究趋势
    • NTRK融合遗传基因的盛行率分析
    • NTRK融合遗传基因的发病率分析
    • 被给病人药TRK抑制剂的患者人口 (估计值)

第5章 TRK抑制剂相关的资本交易 (M&A)的分析

  • 资本交易 (企业合并、收购 (M&A),事业合作)

第6章 TRK抑制剂开发平台医药品的专利分析

第7章 TRK抑制剂的开发平台医药品分析

  • 开发平台医药品分析:各开发阶段
    • 登记前阶段的开发平台医药品
    • 第三阶段 (III期)的开发平台医药品
    • 第二阶段 (II期)的开发平台医药品
    • 第一阶段 (I期)的开发平台医药品
    • 前临床开发平台医药品
    • 初期的研发产品线医药品
    • 开发休止、中止的开发平台医药品
  • 开发平台医药品分析:各地区
  • 开发平台医药品分析:各给药途径
    • 口服药
    • 外用制剂、注射药
  • 开发平台医药品分析:各分子类型
  • 开发平台医药品分析:各标的受体
  • 开发平台医药品分析:各适应症
  • 开发平台医药品分析:企业的各类型

第8章 开发平台医药品的概要与开发里程碑

  • 登记前阶段
  • 第三阶段 (III期)
  • 第二阶段 (II期)
  • 第一阶段 (I期)

第9章 临床实验概要

  • 临床实验结果分析
    • 主要的临床实验的结果:第三阶段
    • 主要的临床实验的结果:第二阶段
    • 主要的临床实验的结果:第一阶段
  • 进行中的临床实验概要
  • 最近完成的临床实验概要
  • 计划中临床实验概要

第10章 开发平台医药品估计核准时间轴

  • 分析方法
  • 美国国内/国外估计核准计划

第11章 市场机会的评估:企业间的互相比较

第12章 现在、未来的竞争情形

  • 新兴企业
    • 主要的新兴企业的简介
目录
Product Code: GERPH1903

GervanoRA's pipeline analysis and opportunity assessment report "NTRK Gene Fusion Cancers - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020" provides detailed analytics on the Epidemiology of NTRK Gene Fusion Cancers in different regions worldwide through a keen full assessment on historical and global trends of prevalence and incidence of NTRK gene fusion-positive cancers. Based on a literature survey and further validation through the KOL process, the report emphasizes finding out the affected population with NTRK gene fusion-positive cancers by geography (US, Europe, and Worldwide) and by majorly affected cancer types. The report even provides insights on TRK Inhibitors' foreseen market opportunities considering the TRK Inhibitor therapies are the only option to treat NTRK gene fusion-positive cancers. Report further analyzed and assessed the total forecasted market into two portions considering broader scope the TRK Inhibitors to treat indications like Neurodegenerative Diseases, Gastrointestinal Diseases and addiction conditions other than NTRK gene fusion-positive cancers. The report outlines how many people can undergo TRK Inhibitor therapies by 2029, and potential market value of NTRK gene fusion-positive cancers, and the market value of TRK Inhibitors meant to treat other indications other than NTRK gene fusion-positive cancers.

TRK Inhibitors pipeline molecules have been analysed for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitor drugs development pipeline.

The report has been divided into segments like TRK InhibitorsTherapies Overview and Epidemiological Studies, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Indication and Pipeline Analytics by Company Type.

The report has covered more than 50 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)

Epidemiological Studies of NTRK Gene Fusion Positive Cancers

  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage Pipeline Drug Candidates and Filed Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Filed, Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE TRK INHIBITORS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF TRK INHIBITORS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY INDICATION
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

CHAPTER 04: TRK INHIBITORS THERAPIES OVERVIEW AND EPIDEMIOLOGICAL STUDIES

  • 4.1. INTRODUCTION
  • 4.2. TRK INHIBITORS THERAPIES - DEVELOPMENT ASSESSMENTS
  • 4.3. SCOPE OF TRK INHIBITORS THERAPIES
  • 4.4. DETECTION OF PATIENTS WITH NTRK FUSION CANCERS
  • 4.5. DISCOVERY OF NTRK GENE FUSIONS IN CANCERS
  • 4.6. APPROVED TRK INHIBITOR PRODUCTS
  • 4.7. EPIDEMIOLOGICAL STUDIES OF NTRK GENE FUSIONS
    • 4.7.1. GLOBAL AND HISTORICAL TRENDS
    • 4.7.2. PREVALENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.2.1. PREVALENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.2.2. PREVALENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
      • 4.7.2.3. PREVALENCE OF NTRK GENE FUSIONS BY AGE GROUP
    • 4.7.3. INCIDENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.3.1. INCIDENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.3.2. INCIDENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
    • 4.7.4. ESTIMATED PATIENT POPULATION WHO RECEIVE TRK INHIBITORS

CHAPTER 05: DEALS (M&A) ANALYTICS OF TRK INHIBITORS

  • 5.1. DEALS (MERGERS/ACQUISITIONS/COLLABORATIONS)

CHAPTER 06: PATENT ANALYTICS OF TRK INHIBITORS PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF TRK INHIBITORS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PRE-REGISTRATION STAGE PIPELINE DRUGS
    • 7.1.2. PHASE III PIPELINE DRUGS
    • 7.1.3. PHASE II PIPELINE DRUGS
    • 7.1.4. PHASE I PIPELINE DRUGS
    • 7.1.5. PRE-CLINICAL PIPELINE DRUGS
    • 7.1.6. EARLY R&D PIPELINE DRUGS
    • 7.1.7. INACTIVE AND DISCONTINUED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 7.3.1. PIPELINE ANALYTICS BY ORAL ROUTE OF ADMINISTRATION
    • 7.3.2. PIPELINE ANALYTICS BY TOPICAL AND INJECTABLE ROA
  • 7.4. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.5. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 7.6. PIPELINE DRUGS ANALYTICS BY INDICATIONS
  • 7.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 8.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.4. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

  • 9.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 9.1.1. KEY PHASE III CLINICAL TRIAL RESULTS
    • 9.1.2. KEY PHASE II CLINICAL TRIAL RESULTS
    • 9.1.3. KEY PHASE I CLINICAL TRIAL RESULTS
  • 9.2. ONGOING CLINICAL TRIALS SUMMARY
  • 9.3. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
  • 9.4. PLANNED CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

  • 10.1. METHODOLOGY
  • 10.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 12.1. EMERGING COMPANIES
    • 12.1.1. EMERGING COMPANY PROFILES